Currently Viewing:
In Focus Blog
Currently Reading
PrEP for HIV Prevention: Essential for Ending the Epidemic, but Out of Reach for Many
July 24, 2018 – Jaime Rosenberg
GAO Report Details Zika Preparedness Shortcomings, Outlines Next Steps
May 25, 2017 – Christina Mattina
Should an Opioid Tax Be a Tool to Fight an Epidemic?
April 13, 2017 – Mary Caffrey
Heart Attack Risk Nearly Doubles for HIV Patients
December 23, 2016 – Mary Caffrey
Deaths From Hepatitis C Virus Hit All-Time High, CDC Reports
May 04, 2016 – Mary Caffrey
20% in US Have Family Member Addicted to Opioids; Most Say Not Enough Being Done
May 03, 2016 – Mary Caffrey
On World AIDS Day, the Evidence for Prevention With Anti-Retroviral Therapy Is Powerful
December 01, 2015 – Mary K. Caffrey
Kaiser Poll Finds Strong Support to Control Drug Prices
April 21, 2015 – Mary K. Caffrey
Aetna Faces Class Action Lawsuit Over Mail-Order Requirement for HIV Drugs
December 29, 2014 – Mary K. Caffrey

PrEP for HIV Prevention: Essential for Ending the Epidemic, but Out of Reach for Many

Jaime Rosenberg
Despite pre-exposure prophylaxis (PrEP) being crucial for preventing new HIV infections and working toward an end to the epidemic, the treatment is still out of reach for many.
As public health officials from all corners of the globe try to get a hold of, and end, the HIV epidemic, many are recognizing the importance of not only treating existing diagnoses, but also preventing new ones. This is where pre-exposure prophylaxis (PrEP) comes in.

Marketed as Truvada, Gilead’s PrEP gained FDA approval for HIV prevention in 2012. Since its approval, usage among people in the United States has significantly increased. Between 2012 and 2016, there was an 880% increase in PrEP users, with an average 73% increase year-over-year. When adhered to consistently, PrEP reduces the risk of acquiring HIV by over 90%.

“This is truly the first medical intervention we’ve had to prevent HIV in the entire history of the epidemic,” said Michael Kharfen, senior deputy director, HIV/AIDS, Hepatitis, STD, and TB Administration, Washington, DC, health department. “We’ve had other tools to prevent HIV acquisition or transmission, such as condoms or clean needles for those using drugs, but we’ve never had an opportunity like this.”

However, despite PrEP being essential for preventing new infections and working toward an end to the epidemic, the treatment is still out of reach for many. Just 5 states account for nearly 50% of PrEP users: New York, California, Florida, Texas, and Illinois. While the south accounted for more than half (52%) of all new HIV diagnoses in 2016, it accounted for just 30% of all PrEP users.

In addition to geographic disparities, there are also demographic ones. According to a CDC analysis of 2015 US data, 44% of African Americans  and 25% of Latinos could have potentially benefited from PrEP. However, just 1% of that African American population and 3% of that Latino population were prescribed PrEP.

An overwhelming majority (93%) of PrEP users in 2016 were men. In an effort to address the significant gender disparity, state health departments have been implementing outreach and education efforts. Washington, DC’s, health department has been incorporating PrEP education into broader health services, such as family planning and reproductive health.

In June, Gilead began a television ad campaign designed to “encourage candid conversations around sexual health and promote public awareness of HIV prevention.” The ads will run through August.

However, getting the word out about PrEP and increasing awareness has proven to be just one hurdle; high cost-sharing and out-of-pocket (OOP) costs provide another. Six years following its approval, the treatment comes with a monthly $1600 price tag. While insurance typically covers the treatment, those uninsured or underinsured are left with a hefty bill.

“When we think about the price of the pill being as expensive as it is, if you were to get an HIV diagnosis and a doctor said here’s a pill that will keep you from dying, you’re probably going to be more willing to pay for a pill that will stop you from dying than to pay for a pill that will prevent you from getting the disease,” explained Joey Mattingly, PharmD, MBA, assistant professor, University of Maryland School of Pharmacy. “And that’s a problem. We have to continue educating people on their risk.”

To fill the financial gaps for the uninsured or underinsured, Gilead has implemented assistance programs to help mitigate costs. However, patients are not always aware of these assistance programs, said Mattingly. When they head to the pharmacy counter and see the price of the treatment, they might not know these programs are available to them, and the pharmacist helping them might not either.

And while these programs have been critical in expanding access for those using them, they sometimes present consumers with barriers, most recently with copay accumulator policies, which affects those who use copay cards, explained Amy Killelea, JD, director, health systems integration, National Alliance of State and Territorial AIDS Directors (NASTAD). Under these policies, which are not highly publicized, when a consumer uses their card, it does not go toward their deductible or OOP maximum.

Related Articles

Despite Increasing Rates of PrEP Usage, Disparities Remain Among African Americans, Latinos
FDA Expands Indication for PrEP to Reduce Risk of HIV in Adolescents
Mobile Health Intervention for HIV Improves Retention in Care, Patient Outcomes
MANNA: Providing Nutritious Meals and a Sense of Community to People Living With HIV
Urgent Change in Approach to HIV Pandemic Is Needed, Report Says
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up